AUTHORS

Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

The Market Will Pay for Its Complacency

Participants largely have ignored the risks to stocks posed by the makeup of the government and the lingering coronavirus, and that could be costly.

This Long-Only Investor Feels Stuck as 2021 Begins

It's hard to find value in a picked-over market trading at all-time highs, which leaves this participant building his cash position.

Looking to Exploit a Few Pandemic Trends That Will Continue in 2021

The virtual work force, online shopping and a love of pets are not going to go away even after the coronavirus abates.

3 Predictions for 2021 and How They'll Impact Stocks

Look for a weaker dollar to perk up the energy sector, the exodus from big cities to continue, and gun and ammo sales to remain strong

Here Are 2 'Stocking Stuffers' for Covered Call Aficionados

I added to my stake in UniQure and initiated a new position in Lexicon Pharmaceuticals.

Look What Insiders Are Buying Now

Here are three interesting names that have seen some significant insider buying in recent weeks.

2 Hot Biotech Stocks That No Longer Are Bargains

Ocular Therapeutix and TG Therapeutics are still promising companies, but their recent runs higher make them pricey at this point.

Signs of Froth in the Market Abound

They leave investors in a precarious position, as there is not a lot of a value left in what has become a very picked-over market.

2 Potential Acquisition Targets as Biotech Deal Activity Picks Up

BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.

Stocking Stuffers: 3 Stocks Under $5

Christmas is coming soon and these equities are well positioned for 2021.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight